News Column

Protalex Announces Preliminary Unblinded Findings from Cohorts 1-4 of U.S. Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, announced it has completed analysis of certain key parameters from its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA) (PRTX-100-104 Study). The primary endpoint of the study is to assess safety and tolerability, with secondary objectives to examine the effects of PRTX-100 on measures of disease activity, assessing the immunogenicity and evaluating the pharmacokinetic (PK) parameters after repeated doses, and determining possible relationships between the immunogenicity of PRTX-100 and safety, PK and efficacy parameters (see also Pharmaceutical Companies).

PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The unblinded analysis included 41 patients recruited at five U.S. clinical sites in the first four dosing cohorts of the five-cohort study through completion of the 25-week study protocol.

The preliminary results indicated that PRTX-100 was generally safe and well tolerated and the Adverse Event (AE) profile was consistent with prior trials results. There were no immediate hypersensitivity reactions, nor any treatment-related Serious Adverse Events (SAEs) evident and no expedited reports to the U.S. Food and Drug Administration (FDA) were required. Pharmacokinetic analyses indicated a roughly linear increase in plasma maximum concentrations with increasing doses of 1.5, 3.0, 6.0, and 12mcg/kg.

Moreover, the study revealed positive effects of PRTX-100 treatment on certain measures of disease activity, although these effects were not statistically significant. At the higher doses, PRTX-100 showed activity comparable to existing well known biologics with apparent onset of action occurring subsequent to the fifth and final dose. For example, four weeks following the last PRTX-100 dose (Day 57), 32% of active-treated and 13% of placebo-treated patients had attained an ACR50 response. At day 113, 29% of the active-treated patients who received 6 or 12 mcg/kg PRTX-100 plus methotrexate achieved DAS28-CRP scores less than 2.6 (remission), while the placebo-treated patients showed no remission. Notably, among all patients treated with PRTX-100, 43% had DAS28-CRP < 3.2 (low disease activity) on both Day 57 and Day 85, while only 14% of placebo-treated patients showed such a reduction in RA disease activity on these days.

The Company expects to submit an interim clinical study report to the FDA in the third quarter of 2014.

Additionally, 16 out of 20 patients in the final cohort of the 104 Study (Cohort 5) have completed dosing though Day 85, and per protocol, all patients will receive their last doses in July 2014. Similar to subjects in Cohorts 1 through 4, patients in Cohort 5 are receiving five weekly doses of PRTX-100 or placebo, but additionally will receive four monthly "maintenance" doses thereafter.

Keywords for this news article include: Pharmaceutical Companies, Therapy, Protalex Inc., Joint Diseases, Rheumatoid Arthritis, Adverse Drug Reaction, Musculoskeletal Diseases, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters